Skip to content

Morphotek, founded in 2001, was a biopharmaceutical company developing optimized therapeutic monoclonal antibodies through the use of its proprietary human antibody platform. The company was acquired by Eisai for $325M in 2007.

Latest News from Morphotek

Next